A novel series of potent cytotoxic agents targeting G2/M phase of the cell cycle and demonstrating cell killing by apoptosis in human breast cancer cells. | LitMetric
Breast cancer, a leading cause of mortality in women, warrants the development and biological evaluation of new anticancer agents. A novel series of thiopyridine triazine derivatives was synthesized and investigated in the human breast cancer cell line, MDA-MB-468. SM40, the most potent derivative, induced a G2/M arrest and apoptosis with a possible involvement of p53. The cytotoxicity of SM40 was also examined against the NCI 60 cell line panel and its potency was rationalized using molecular modeling. Results suggest that SM40 is a promising cytotoxic agent.
Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Olympic-ro 43-gil, Songpa-gu, 05505, Seoul, Republic of Korea.
Purpose: To determine how often non-mass lesions are seen in screening breast ultrasounds, and analyze their ultrasound features according to the ultrasound lexicon to find features suggestive of malignant non-mass lesions.
Methods: This study is a single center retrospective study for nonmass lesions on screening breast ultrasound. Among 21,604 patients who underwent screening breast US, there were 279 patients with nonmass lesions.
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to expand the current treatment landscape for immune checkpoint inhibitors in hormone receptor positive and HER2 positive breast cancer. Antibody drug conjugates are FDA approved for triple negative and HER2+ disease, and are being studied in combination with immune checkpoint inhibitors.
Black women experience disproportionate breast cancer-related mortality, with similar overall incidence to White women. Approaches to address these racial health disparities should be multifaceted. Universal genetic counseling and testing for Black women could represent one dimension of a comprehensive approach in guiding early identification of those more likely to experience higher breast cancer-related mortality.
Background: In the DESTINY-B04 trial, patients with pretreated HER2 low metastatic breast cancer (defined as immunohistochemistry score of 1+ or 2+ and negative in situ hybridization) had significant survival improvement with Trastuzumab therapy.
Methods: The goal of our study was to compare the HER2 immunohistochemistry scores of paired primary and metastatic breast cancer, with emphasis on HER2 low criteria and its implications for detailed immunohistochemistry interpretation. Using the pathology database from 2011, we identified 272 cases of primary breast cancers with paired metastases.
Background: The use of the residual cancer burden (RCB) for assessing breast cancer after neoadjuvant therapy (NAT) is increasingly common, but the prognostic difference between RCB 0 and RCB I is unclear.
Methods: We systematically reviewed literature from PubMed, Embase, Web of Science, and oncology conferences until September 24, 2023. We used fixed- and random-effects models to calculate hazard ratio (HR) with 95% confidence interval (CI) for event-free survival (EFS), overall survival (OS), and distant disease-free survival (DDFS).
